Post-TNFalpha
(Unterschied zwischen Versionen)
| Zeile 1: | Zeile 1: | ||
{{tp|p=32278362|t=2020. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed |pdf=|usr=}} | {{tp|p=32278362|t=2020. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed |pdf=|usr=}} | ||
{{tp|p=32382744|t=2020. Anti-TNF-alpha Agents in Inflammatory Bowel Disease and Course of COVID-19.|pdf=|usr=008}} | {{tp|p=32382744|t=2020. Anti-TNF-alpha Agents in Inflammatory Bowel Disease and Course of COVID-19.|pdf=|usr=008}} | ||
| + | {{tp|p=32473011|t=2020. Potential inhibition of COVID-19-driven pneumonia by immunosuppressive therapy and anti-TNFalpha antibodies: a case report.|pdf=|usr=007}} | ||
Version vom 28. Juni 2020, 10:41 Uhr
32278362 2020. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
32382744 2020. Anti-TNF-alpha Agents in Inflammatory Bowel Disease and Course of COVID-19.
32473011 2020. Potential inhibition of COVID-19-driven pneumonia by immunosuppressive therapy and anti-TNFalpha antibodies: a case report.
